The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

So could you add weight to your portfolio by taking a slice of Eli Lilly, the US maker of Mounjaro, which is now being ...

A new investigational medication known as amycretin has shown significant potential in promoting weight loss, according to ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The new weight-loss tablet was developed in a lab and is based on “a type of β2 agonist.” As explained in the news release: ...

By Vijay Kumar Malesu A new trial reveals that once-weekly amycretin injections help adults shed more than 20% of their body weight, marking a major leap forward in obesity care and metabolic health.

Amycretin — a novel obesity treatment that targets both GLP-1 and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.